News coverage about Innocoll Holdings PLC (NASDAQ:INNL) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Innocoll Holdings PLC earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.3863592281347 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Innocoll Holdings PLC (NASDAQ INNL) remained flat at $2.35 during mid-day trading on Friday. The company had a trading volume of 392,951 shares. The stock has a 50 day moving average price of $2.25 and a 200-day moving average price of $1.58. Innocoll Holdings PLC has a 52-week low of $0.53 and a 52-week high of $6.51.

Several analysts recently commented on INNL shares. FBR & Co reiterated a “hold” rating on shares of Innocoll Holdings PLC in a research report on Tuesday, July 4th. Zacks Investment Research cut Innocoll Holdings PLC from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $3.75.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at

Innocoll Holdings PLC Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

Insider Buying and Selling by Quarter for Innocoll Holdings PLC (NASDAQ:INNL)

Receive News & Stock Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related stocks with our FREE daily email newsletter.